OakChart

Emergent Biosolutions Inc

EBSHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NYSE·Nov 11 • 3:59 PM ET

6.04-0.01 (-0.17%)
2026-11-12 03:22 CET
Market cap
310.55 USD m
Revenue, TTM
649.10 USD m
Net income, TTM
-260.70 USD m
Free cash flow, TTM
188.40 USD m
EPS diluted, TTM
-5.10
P/E
-
Compare

Price

EBS against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.002.2M4.3MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26EBSclose 6.0420-day 6.3850-day 6.52200-day 7.796.0452w low

57.0% under the 52-week high of 14.06 on 7 Jan 2026. 52-week low 4.36 on 10 Aug 2026. Last 15 sessions, 32.6% high to low

Volume 0.44× normal · the line is the 50-bar volume average

Profile

EBS
52-week range, 17% of the way up
4.3614.06

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company's Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

IndexRUT
Employees900
IPONov 15, 2006
Beta2.38
ATR, 14d0.42
Rel volume0.44
Short float20.85%
Insider own5.96%
Inst own89.07%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap310.55M
Enterprise Value647.35M
Income-260.70M
Sales649.10M
Book/sh6.11
Cash/sh3.44
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees900
IPONov 15, 2006

Ratios

P/E-
Forward P/E5.77
PEG6.95
P/S0.48
P/B0.99
P/C1.76
P/FCF1.65
EV/EBITDA5.32
EV/Sales1.00
Quick Ratio2.27
Current Ratio4.58
Debt/Eq1.64
LT Debt/Eq1.64
Option/ShortYes / Yes

Earnings

EPS (ttm)-5.10
EPS next Y1.05
EPS next Q-0.16
EPS this Y-81.07%
EPS next Y261.33%
EPS next 5Y0.83%
EPS past 3/5Y- -30.38%
Sales past 3/5Y-12.72% -13.74%
EPS Y/Y TTM-456.60%
Sales Y/Y TTM-17.72%
EPS Q/Q-170.34%
Sales Q/Q-52.40%
EarningsNov 02 AMC
EPS/Sales Surpr.8.02% -10.73%

Ownership

Insider Own5.96%
Insider Trans-0.77%
Inst Own89.07%
Inst Trans3.52%
ROA-21.23%
ROE-58.21%
ROIC-31.58%
Gross Margin39.15%
Oper. Margin4.95%
Profit Margin-40.16%
SMA20-5.40%
SMA50-7.43%
SMA200-22.50%
Trades-

Technical

Shs Outstand51.30M
Shs Float48.35M
Short Float20.85%
Short Ratio8.62
Short Interest10.08M
52W High14.06 -57.04%
52W Low4.36 38.53%
Volatility4.28% 6.76%
ATR (14)0.42
RSI (14)42.51
Beta2.38
Rel Volume0.44
Avg Volume1.17M
Volume516,261

Performance

Perf Week2.37%
Perf Month-12.59%
Perf Quarter34.52%
Perf Half Y-27.49%
Perf YTD-51.13%
Perf Year-44.49%
Perf 3Y202.00%
Perf 5Y-82.96%
Perf 10Y-80.45%
Recom2.33
Target Price10.00
Prev Close6.05
Price6.04
Change %-0.17%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 21, 2026ResumedJJP MorganUnderweight
Dec 30, 2024InitiatedHH.C. WainwrightBuy$15+148.3%
Aug 22, 2024InitiatedRRodman & RenshawBuy$16+164.9%
Mar 07, 2024UpgradeTThe Benchmark CompanyHold → Buy$5-17.2%
Nov 20, 2023ResumedJJP MorganUnderweight
Aug 29, 2023DowngradeTThe Benchmark CompanyBuy → Hold
Apr 10, 2023UpgradeTThe Benchmark CompanyHold → Buy$22+264.2%
Mar 17, 2023DowngradeJJP MorganNeutral → Underweight$23 → $9+49.0%
Nov 10, 2022DowngradeTThe Benchmark CompanyBuy → Hold
Apr 29, 2022DowngradeCCantor FitzgeraldOverweight → Neutral

Peers

Mkt cap
TickerCompanyMkt cap
SIGASIGA Technologies Inc225.63M
KMDAKamada Ltd469.02M
INDVIndivior Pharmaceuticals Inc5.97B
TEVATeva- Pharmaceutical Industries Ltd50.45B
ADMAAdma Biologics Inc2.93B
NVAXNovavax Inc1.65B
TNXPTonix Pharmaceuticals Holding Corp75.20M
GOVXGeovax Labs Inc1.10M
VIRVir Biotechnology Inc2.25B
SNGXSoligenix Inc7.51M

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
DONALD DEGOLYERDirectorOct 07 '26Proposed Sale7.0917,800126,120Oct 07 04:03 PM
DeGolyer Donald WDirectorOct 07 '26Sale7.0917,800126,202111,921Oct 07 03:45 PM
Williams Paul AnthonySVP, Products BusinessOct 01 '26Sale6.533,00019,590156,098Oct 05 09:16 AM
PAUL WILLIAMSOfficerOct 01 '26Proposed Sale6.533,00019,592Oct 01 04:20 PM
Williams Paul AnthonySVP, Products BusinessJul 01 '26Sale8.403,00025,200159,098Jul 02 12:57 PM
PAUL WILLIAMSOfficerJul 01 '26Proposed Sale8.403,00025,205Jul 01 04:12 PM
Dayal Sujata TyagiDirectorMay 01 '26Sale8.4013,761115,610100,563May 04 05:30 PM
DeGolyer Donald WDirectorMay 01 '26Sale8.4015,481129,994129,721May 04 05:30 PM
Katkin KeithDirectorApr 30 '26Sale8.2815,481128,18396,294May 04 05:29 PM
Zoon Kathryn CDirectorMay 01 '26Sale8.4017,202144,45379,941May 04 05:28 PM
SUJATA TYAGI DAYALDirectorMay 01 '26Proposed Sale8.4013,761115,612May 01 04:20 PM
KATHRYN ZOONDirectorMay 01 '26Proposed Sale8.4017,202144,492May 01 04:03 PM
DONALD DEGOLYERDirectorMay 01 '26Proposed Sale8.4015,481130,064May 01 04:02 PM
KEITH KATKINDirectorApr 30 '26Proposed Sale8.2815,481128,141Apr 30 04:11 PM

Held by

AUM
TickerCompanyAUM
AVUVAvantis U.S. Small Cap Value ETFAUM: 32.39B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
DFSVUS Small Cap Value Portfolio ETF Class SharesAUM: 8.52B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SMLFiShares U.S. Small-Cap Equity Factor ETFAUM: 4.26B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
DFATU.S. Targeted Value Portfolio-ETF Class SharesAUM: 14.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-02-0.360-0.391-0.640110123.222
2026Q22026-08-050.600-0.085-3.492234.3177.52
2026Q12026-04-300.210-0.2500.074156.11451
2025Q42026-02-26-0.4300.110-1.042148.7217.51
2025Q32025-10-291.060-0.1200.906231.11942
2025Q22025-08-060.160-0.413-0.221140.9146.373
2025Q12025-05-070.7100.4401.187222.22192
2024Q42025-03-030.050-0.503-0.578194.7249.53
2024Q32024-11-061.3700.1032.065293.8290.333
2024Q22024-08-06-2.320-1.135-5.382254.71902
2024Q12024-05-010.590-0.9800.172300.4220.252
2023Q42024-03-06-0.770-0.190-0.954276.6293.413
2023Q32023-11-08-0.528-0.223-5.085270.5237.433
2023Q22023-08-08-1.060-0.647-5.154337.9216.173
2023Q12023-05-09-3.170-1.294-3.645165.1159.735
2022Q42023-02-27-0.3100.044-1.764330.7297.185

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY2.3302.2411.220782.4782.75
2019FY2.9102.9601.0401,1061,104
2020FY7.8807.3485.6711,5551,546
2021FY6.0205.8854.0571,7931,738
2022FY-2.230-1.902-4.2241,1211,087
2023FY-6.230-4.841-14.8541,0491,067
2024FY-0.230-0.837-3.5961,0441,098
2025FY1.5302.0500.930742.9809.4
2026FY-0.290--646.79
2027FY-1.046--703.33
2028FY-1.568--628.15
2029FY-0.900--963.2

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-03301137.5126151.51
2026Q4S2026-11-02300143.5126153
2026Q4S2026-10-21300143.5126153
2026Q4S2026-10-20301143.5126153
2026Q4S2026-08-20302143.5126153
2026Q4S2026-08-07202139.5126153
2026Q4S2026-08-06201169.45153185.9
2026Q4S2026-07-15200190.45185.9195
2026Q4S2026-05-01211190.45185.9195
2026Q4S2026-03-06201202.5180225
2026Q4S2026-02-27200252.5225280
2026Q4S2025-11-11100280280280
2026Q4S2025-11-10100280280280
2026Q4S2025-11-09100280280280

Estimate history

EPS, annual1.7081.221.045.6714.057-4.224-14.854-3.5960.928-5.0973
Period201720182019202020212022202320242025TTM
EPS, quarterly2.065-0.5781.187-0.2210.906-1.0420.074-3.492-0.637
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual560.9782.411061555.41773.61117.51049.31043.6742.9649.1
Period201720182019202020212022202320242025TTM
Sales, quarterly293.8194.7222.2140.9231.1148.7156.1234.3110
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual49.451.251.753.151.350.152.254.352.151.3
Period201720182019202020212022202320242025MRQ
Shares, quarterly54.154.354.553.752.752.151.851.351.3
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue649.10742.901,043.601,049.301,117.501,773.601,555.401,106.00782.40
Cost of Goods Sold Incl. D&A395.00392.30738.40756.80750.40803.70552.10467.40344.20
Gross Profit254.10350.60305.20292.50367.10969.901,003.30638.60438.20
Selling, General and Administrative Excl. Other222.00240.40363.60464.50526.00583.90508.80499.70329.00
Research and Development39.3053.8064.90107.80188.30235.20205.50226.20142.80
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income32.10110.20-58.40-172.00-158.90386.00494.50138.90109.20
Interest Expense45.4059.3071.0096.8037.2028.7027.4039.009.90
Unusual Expense226.5022.3050.30554.4011.1044.6064.6024.2019.40
Net Income Before Taxes-240.0082.80-142.90-731.20-219.00303.20407.2077.4081.50
Income Taxes20.7030.2047.7029.30-7.4083.70102.1022.9018.80
Consolidated Net Income-260.7052.60-190.60-760.50-211.60219.50305.1054.5062.70
Net Income From Continuing Operations-260.7052.60-190.60-760.50-211.60219.50305.1054.5062.70
Net Income-260.7052.60-190.60-760.50-211.60219.50305.1054.5062.70
EPS (Recurring)-2.041.20-2.93-7.27-4.074.636.511.361.48
EPS (Basic, Before Extraordinaries)-5.040.98-3.60-14.85-4.224.105.791.061.25
EPS (Diluted)-5.100.93-3.60-14.85-4.224.065.671.041.22
EBITDA121.60208.5053.60-42.90-10.00512.30608.90249.80170.50
Non-Operating Income (Expense)-0.2054.2036.8092.00-11.80-9.504.701.701.60
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.4612.8014.2218.2535.6333.5037.2319.4918.33
Price To Earnings Ratio----15.1210.2215.8952.6148.55
Price To Sales Ratio0.520.940.490.120.531.333.102.563.89
Gross Margin39.1547.1929.2427.8832.8554.6964.5057.7456.01
Operating Margin4.9514.83-5.60-16.39-14.2221.7631.7912.5613.96
Net Margin-40.167.08-18.26-72.48-18.9412.3819.624.938.01
Shares Outstanding51.3052.1054.3052.2050.1051.3053.1051.7051.20
Market Capitalization310.55310.55518.00124.52589.182,338.634,748.722,785.113,020.02

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue110.00234.30156.10148.70231.10140.90222.20194.70
Cost of Goods Sold Incl. D&A90.10114.3088.50102.10102.0083.40105.70134.70
Gross Profit19.90120.0067.6046.60129.1057.50116.5060.00
Selling, General and Administrative Excl. Other47.9053.8057.1063.2052.3057.0067.9069.90
Research and Development7.509.2010.5012.1013.5013.0015.209.20
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-28.0066.2010.50-16.6076.800.5048.60-9.90
Interest Expense9.7010.0011.0014.7015.2014.7014.7014.80
Unusual Expense-1.00211.30-8.4024.600.30-1.10-1.30-0.40
Net Income Before Taxes-36.40-166.3013.40-50.7057.60-16.8092.70-27.60
Income Taxes-3.7013.906.603.906.40-4.8024.703.70
Consolidated Net Income-32.70-180.206.80-54.6051.20-12.0068.00-31.30
Net Income From Continuing Operations-32.70-180.206.80-54.6051.20-12.0068.00-31.30
Net Income-32.70-180.206.80-54.6051.20-12.0068.00-31.30
EPS (Recurring)-0.65-0.63-0.03-0.710.91-0.241.17-0.58
EPS (Basic, Before Extraordinaries)-0.64-3.490.13-1.040.96-0.221.25-0.58
EPS (Diluted)-0.64-3.490.07-1.040.91-0.221.19-0.58
EBITDA-10.6090.7034.606.90100.6024.5074.6016.10
Non-Operating Income (Expense)0.30-11.205.505.20-3.70-3.7057.50-3.30
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense3.325.451.504.193.793.631.193.40
Price To Earnings Ratio--10.009.553.60---
Price To Sales Ratio0.520.560.690.870.630.410.290.50
Gross Margin18.0951.2243.3131.3455.8640.8152.4330.82
Operating Margin-25.4528.256.73-11.1633.230.3521.87-5.08
Net Margin-29.73-76.914.36-36.7222.15-8.5230.60-16.08
Shares Outstanding51.3051.3051.8052.1052.7053.7054.5054.30
Market Capitalization310.55432.38429.70649.15470.56346.29264.08518.00

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments209.10105.60111.70642.60576.30621.50168.00112.40179.30
Short Term Receivables84.20154.50191.00159.20278.90230.90275.30272.30146.10
Inventories343.40311.70328.90350.70344.50307.00222.50205.80142.80
Other Current Assets25.8026.9047.9057.9070.2036.5020.4030.3017.20
Total Current Assets662.50598.70679.501,210.401,269.901,195.90686.20620.80485.40
Net Property, Plant & Equipment216.00282.30399.00837.00828.40675.10567.00510.20407.20
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets436.50501.50566.60947.00829.50929.801,008.501,071.30168.70
Deferred Tax Assets13.407.2011.70---13.4013.402.80
Other Assets3.607.20178.10171.9029.9082.4052.2013.706.10
Total Assets1,332.001,396.901,834.903,166.302,957.702,883.202,327.302,229.401,070.20
Short Term Debt Incl. Current Port. of LT Debt2.402.70417.20963.1037.4039.2016.4010.100.00
Accounts Payable55.6060.90112.20103.50128.90136.1094.8080.7041.80
Income Tax Payable6.80------4.500.00
Other Current Liabilities67.4098.80121.90162.30207.70209.20105.10105.1058.30
Total Current Liabilities132.20162.40651.301,228.90374.00384.50216.30200.40100.10
Long Term Debt581.30673.40460.30463.30833.60868.80820.50784.5013.50
Provision for Risks Charges0.000.000.000.000.0034.2026.0054.409.90
Deferred Tax Liabilities51.2048.9058.9059.7093.3053.2063.9067.50-
Other Liabilities44.7029.4015.1026.7045.3095.50112.10111.7034.40
Total Liabilities809.40914.101,185.601,778.601,346.201,436.201,238.801,218.50157.90
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity522.60482.80649.301,387.701,611.501,447.001,088.501,010.90912.30
Total Shareholders Equity522.60482.80649.301,387.701,611.501,447.001,088.501,010.90912.30
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity522.60482.80649.301,387.701,611.501,447.001,088.501,010.90912.30
Total Liabilities & Stockholders Equity1,332.001,396.901,834.903,166.302,957.702,883.202,327.302,229.401,070.20
Book Value Per Share10.038.8912.4427.7031.4127.2521.0519.7418.47
Tangible Book Value Per Share1.65-0.341.588.8015.249.741.55-1.1815.05
Full-Time Employees9009001,6002,5002,4162,2001,8341,7051,256
Price to Book Ratio0.991.020.180.411.383.292.563.002.90
Return on Assets3.86-11.80-30.41-6.917.5211.712.393.808.10
Return on Equity10.46-33.67-74.67-14.0814.3524.075.196.5210.95
Return on Invested Capital4.76-16.49-68.54-11.438.9813.172.853.498.92
Quick Ratio2.411.770.540.702.472.312.142.073.42
Current Ratio5.013.691.040.983.403.113.173.104.85

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-260.7052.60-190.60-760.50-211.60219.50305.1054.5062.70
Depreciation88.0095.80108.80125.10143.30123.80114.50110.7062.20
Other Funds (Non Cash)249.1048.6057.30508.3064.9075.90110.0066.3027.40
Funds from Operations62.30193.00-30.00-136.00-32.00465.20527.20230.40160.90
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital137.80-22.4088.70-70.30-2.10-145.008.80-42.40-119.10
Income Taxes Payable--1.7023.30-16.2028.70-31.30--11.70-5.10
Cash from Operating Activities200.10170.6058.70-206.30-34.10320.20536.00188.0041.80
Capital Expenditures-11.70-13.80-22.90-51.60-359.50-224.10-141.00-86.90-72.10
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-827.70
Sale of Fixed Assets and Businesses5.6038.20118.10270.200.000.000.000.002.60
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses-50.40-5.000.00-6.30-21.800.00-10.00-10.000.00
Other Sources2.5050.0030.000.000.000.000.000.000.00
Cash from Investing Activities-54.0069.40125.20212.30-381.30-224.10-151.00-96.90-897.20
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock-24.50-22.7010.8010.20-77.10-90.1031.608.2015.80
Repurchase of Common Pref Stock-27.20-24.900.000.00-82.10-106.000.000.00-0.10
Sale of Common Pref Stock2.702.2010.8010.205.0015.9031.608.2015.90
Proceedsfrom Stock Options2.202.209.308.400.000.000.000.000.00
Issuance or Reduction of Debt, Net-190.10-112.50-199.60-543.40564.20-35.9054.5013.70781.80
Change in Long Term Debt-190.10-112.50-199.60-543.40564.20-35.9054.5013.70781.80
Issuance of Long Term Debt134.000.00282.8020.00598.000.00441.60130.00784.60
Reduction of Long Term Debt-324.10-112.50-482.40-563.40-33.80-35.90-387.10-116.30-2.80
Net Financing Active Other Cash Flow-3.80-1.40-1.20-2.50-5.90-15.00-16.60-57.80-8.90
Other Financing Activities Uses-3.80-1.40-1.20-2.50-5.90-15.00-16.60-57.80-10.00
Cash from Financing Activities-218.40-136.60-190.00-535.70481.20-141.0069.50-35.90788.70
Exchange Rate Effect0.000.100.00-1.200.50-0.30-1.000.40-0.20
Net Change in Cash-72.30103.50-6.10-530.9066.30-45.20453.5055.60-66.90
Free Cash Flow188.40156.8035.80-257.90-393.6096.10395.00101.10-30.30
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow1.804.4714.15--24.4712.2027.96-
Deferred Taxes & Investment Tax Credit--4.00-5.50-8.90-28.6046.00-2.40-1.108.60

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments176.90140.90161.50209.10249.20271.00
Short Term Receivables77.50190.00121.6084.20149.5079.80
Inventories280.90303.60327.60343.40356.30338.60
Other Current Assets22.9031.5026.9025.8031.9030.10
Total Current Assets558.20666.00637.60662.50786.90719.50
Net Property, Plant & Equipment180.20183.80209.30216.00217.00223.80
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets252.50261.80470.40436.50452.70469.00
Deferred Tax Assets---13.40--
Other Assets4.305.203.103.604.404.80
Total Assets995.201,116.801,320.401,332.001,461.001,417.10
Short Term Debt Incl. Current Port. of LT Debt1.501.5052.802.401.801.80
Accounts Payable52.0050.2039.5055.6057.4063.70
Income Tax Payable4.304.407.206.80--
Other Current Liabilities64.2066.7049.2067.4077.3061.60
Total Current Liabilities122.00122.80148.70132.20136.50127.10
Long Term Debt512.20586.70582.20581.30669.20674.30
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities22.2035.4033.3051.2036.3046.50
Other Liabilities25.6030.5033.1044.7036.5033.00
Total Liabilities682.00775.40797.30809.40878.50880.90
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity313.20341.40523.10522.60582.50536.20
Total Shareholders Equity313.20341.40523.10522.60582.50536.20
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity313.20341.40523.10522.60582.50536.20
Total Liabilities & Stockholders Equity995.201,116.801,320.401,332.001,461.001,417.10
Book Value Per Share6.116.6510.1010.0311.059.99
Tangible Book Value Per Share1.181.551.021.652.461.25
Full-Time Employees---900--
Price to Book Ratio0.990.830.831.120.880.63
Return on Assets-21.23-13.95-0.633.865.179.52
Return on Equity-58.21-40.29-1.6010.4613.9230.24
Return on Invested Capital-3.96-19.420.62-4.954.09-0.99
Quick Ratio2.272.952.082.413.153.00
Current Ratio4.585.424.295.015.765.66

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-32.70-180.206.80-54.6051.20-12.00
Depreciation17.0024.0023.5023.5023.4023.50
Other Funds (Non Cash)-3.30234.90-7.8025.3014.7013.10
Funds from Operations-32.2080.8018.00-4.3079.1010.70
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital132.30-24.70-51.8082.00-81.4095.70
Cash from Operating Activities100.1056.10-33.8077.70-2.30106.40
Capital Expenditures-3.30-2.10-2.40-3.90-3.40-2.90
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses5.400.200.000.000.000.10
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.00-50.400.000.000.000.00
Other Sources2.500.000.000.000.0020.00
Cash from Investing Activities4.60-52.30-2.40-3.90-3.4017.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.00-8.00-8.60-7.90-8.70-6.20
Repurchase of Common Pref Stock-0.10-9.00-9.00-9.10-8.90-6.90
Sale of Common Pref Stock0.101.000.401.200.200.70
Proceedsfrom Stock Options0.000.000.002.200.000.00
Issuance or Reduction of Debt, Net-68.50-16.000.00-105.60-6.900.00
Change in Long Term Debt-68.50-16.000.00-105.60-6.900.00
Issuance of Long Term Debt0.00134.000.000.000.000.00
Reduction of Long Term Debt-68.50-150.000.00-105.60-6.900.00
Net Financing Active Other Cash Flow-0.20-0.40-2.80-0.40-0.30-0.20
Other Financing Activities Uses-0.20-0.40-2.80-0.40-0.30-0.20
Cash from Financing Activities-68.70-24.40-11.40-113.90-15.90-6.40
Exchange Rate Effect0.000.000.000.00-0.201.00
Net Change in Cash36.00-20.60-47.60-40.10-21.80118.20
Free Cash Flow96.8054.00-36.2073.80-5.70103.50
Price to Free Cash Flow1.805.033.464.13355.952.23

Revenue breakdown

All Other2024: 134.90M 2025: 60.10M
Commercial Product2024: 398.90M 2025: 226.10M
Medical Countermeasures (MCM) Product2024: 509.80M 2025: 456.70M
Canada2024: 140.40M 2025: 75.00M
Other countries2024: 80.60M 2025: 136.80M
United States2024: 822.60M 2025: 531.10M
Commercial Products2024: 398.90M 2025: 226.10M
Consolidation, Policy2024: 134.90M 2025: 60.10M
MCM Products2024: 509.80M 2025: 456.70M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3020.85%10.1M48.4M1.22M
2026-10-1520.09%9.7M48.2M1.15M
2026-09-3019.28%9.3M48.2M1.11M
2026-09-1520.30%9.8M48.2M1.13M
2026-08-3122.49%10.8M48.2M1.07M
2026-08-1424.15%11.6M48.2M1.01M
2026-07-3120.72%10.0M48.4M830.95K
2026-07-1521.22%10.3M48.7M828.55K
2026-06-3021.07%10.3M48.7M815.88K
2026-06-1520.06%9.8M48.7M750.71K
2026-05-2920.04%9.8M48.7M820.75K
2026-05-1519.72%9.6M48.7M867.01K
2026-04-3020.07%9.8M48.7M843.65K
2026-04-1519.37%9.6M49.8M905.54K
2026-03-3119.38%9.7M49.8M960.51K
2026-03-1317.82%8.9M49.8M945.39K
2026-02-2718.04%9.0M49.8M877.93K
2026-02-1317.56%8.9M50.5M839.66K
2026-01-3017.10%8.6M50.4M952.52K
2026-01-1517.49%8.8M50.4M1.06M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.002.607.500.000.0000.000.000.986-0.0140.000
call2.001.604.904.7011.8762.000.000.939-0.0460.001
call3.000.805.503.5014.0791.000.000.903-0.0450.002
call4.000.304.900.0015.3570.000.000.854-0.0410.002
call5.000.004.902.0116.2443.000.000.773-0.0330.003
call6.000.250.600.601.56352.002.000.551-0.0270.004
call7.000.000.750.051.9662490.000.370-0.0400.004
call8.000.002.000.052.6032970.000.311-0.0490.003
call9.000.000.400.051.6622080.000.078-0.0130.001
call10.000.000.050.101.96180.000.000.069-0.0140.001
call11.000.000.100.102.2534640.000.062-0.0150.001
call12.000.004.800.012.49516.000.000.057-0.0150.001
put1.000.000.050.006.6730.000.00-0.014-0.0120.000
put2.000.002.250.007.1370.000.00-0.061-0.0450.001
put3.000.004.800.004.8610.000.00-0.097-0.0440.002
put4.000.002.500.003.3160.000.00-0.146-0.0400.002
put5.000.000.300.112.08418.000.00-0.223-0.0330.003
put6.000.150.350.240.9861513.00-0.449-0.0260.004
put7.000.004.901.1012.70929.000.00-0.630-0.0390.004
put8.000.204.901.939.73720.000.00-0.689-0.0480.003
put9.000.705.400.008.7470.000.00-0.922-0.0120.001
put10.002.906.400.009.1890.000.00-0.931-0.0130.001
put11.002.507.300.009.2900.000.00-0.938-0.0130.001
put12.004.908.400.009.9090.000.00-0.943-0.0140.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-048-KCurrent report2026-11-04SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-028-KCurrent report2026-11-02SEC
2026-10-168-KCurrent report2026-10-16SEC
2026-10-07144Filing for proposed sale of securities under Rule 144.SEC
2026-10-074Statement of changes in beneficial ownership of securities2026-10-07SEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-018-KCurrent report2026-08-18SEC
2026-08-14SCHEDULE 13GSEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-05SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-07-31SCHEDULE 13G/ASEC
2026-07-28SCHEDULE 13G/ASEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-01144Filing for proposed sale of securities under Rule 144.SEC
2026-06-298-KCurrent report2026-06-26SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-06-104Statement of changes in beneficial ownership of securities2026-06-08SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC
2026-05-044Statement of changes in beneficial ownership of securities2026-04-30SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1000145.79K2
2026-090000
2026-080000
2026-070025.20K1
2026-060000
2026-0500390.06K3
2026-0400161.94K2
2026-030000
2026-020000
2026-010000
2025-1200263.08K1
2025-1100273.14K2

Institutional holders

Manager% owned
BlackRock, Inc.9.14%
STATE STREET CORP5.68%
AMERICAN CENTURY COMPANIES INC5.37%
DIMENSIONAL FUND ADVISORS LP5.01%
VANGUARD CAPITAL MANAGEMENT LLC4.26%
LSV ASSET MANAGEMENT3.88%
ACADIAN ASSET MANAGEMENT LLC3.77%
GEODE CAPITAL MANAGEMENT, LLC2.48%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2.33%
PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C.2.23%

Funds

Fund% owned
Lord Abbett Short Duration High Yield Fund31.43%
Fidelity High Income Fund20.73%
Fidelity SAI High Income Fund19.64%
iShares Broad USD High Yield Corporate Bond ETF17.82%
AB HIGH INCOME FUND INC15.14%
Fidelity Total Bond Fund14.40%
Virtus Seix Floating Rate High Income Fund10.66%
iShares High Yield Systematic Bond ETF10.18%
Lord Abbett High Yield Fund10.17%
EUPAC Fund9.34%

OakChart. EBS. Cached 15 minutes.